Tearsheet

Charles River Laboratories International (CRL)

Market Price (12/27/2025): $203.7 | Market Cap: $10.0 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Charles River Laboratories International (CRL)

Market Price (12/27/2025): $203.7
Market Cap: $10.0 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%	Trading close to highs Dist 52W High is 0.0%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 112x
1	Attractive yield FCF Yield is 5.4%	Weak multi-year price returns 2Y Excs Rtn is -60%, 3Y Excs Rtn is -86%	Weak revenue growth Rev Chg QQuarterly Revenue Change % is -0.5%
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, mRNA Technology, Show more.		Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0%
3			Key risks CRL key risks include [1] the FDA's phase-out of animal testing requirements, Show more.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%
1	Attractive yield FCF Yield is 5.4%
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, mRNA Technology, Show more.
3	Trading close to highs Dist 52W High is 0.0%
4	Weak multi-year price returns 2Y Excs Rtn is -60%, 3Y Excs Rtn is -86%
5	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 112x
6	Weak revenue growth Rev Chg QQuarterly Revenue Change % is -0.5%
7	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0%
8	Key risks CRL key risks include [1] the FDA's phase-out of animal testing requirements, Show more.

Valuation, Metrics & Events

	12/27/25	2024	2023	2022	2021
Share Price CYE	$203.70	$184.60	$236.40	$217.90	$376.78
Market Cap CYE ($ Bil)	10.0	9.4	12.1	11.1	19.0
Total Debt ($ Bil)	2.6	2.7	3.1	3.1	2.9
Total Cash ($ Bil)	0.2	0.2	0.3	0.2	0.2
Enterprise Value ($ Bil)	12.4	12.1	15.2	14.2	21.9
Valuation Ratios
P/S TTM	2.5	2.3	2.9	2.8	5.4
P/EBIT TTM	112.3	43.2	16.9	16.2	34.2
P/E TTM	-120.1	921.1	25.5	22.8	48.5
P/FCF TTM	18.4	18.9	33.1	37.5	35.6
Sector Ratios
P/S TTM (Sector)	4.3	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3	-2.6
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/27/25	2024	2023
Share Price CYE	$203.70	$184.60	$236.40
Market Cap CYE ($ Bil)	10.0	9.4	12.1
Total Debt ($ Bil)	2.6	2.7	3.1
Total Cash ($ Bil)	0.2	0.2	0.3
Enterprise Value ($ Bil)	12.4	12.1	15.2
Valuation Ratios
P/S TTM	2.5	2.3	2.9
P/EBIT TTM	112.3	43.2	16.9
P/E TTM	-120.1	921.1	25.5
P/FCF TTM	18.4	18.9	33.1
Sector Ratios
P/S TTM (Sector)	4.3	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	CRL	S&P 500
REVENUE GROWTH	VERY POOR
Rev LTM ($ Bil)	4.0
Rev Chg Q	-0.5%	7.3%
Rev Chg LTM	-0.9%	6.1%
Rev Chg 3Y Avg	2.3%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	0.4
CFO LTM ($ Bil)	0.7
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	8.8%	18.8%
CFO/Rev LTM	18.6%	20.4%
Net Inc Mgn	-2.1%	13.1%
VALUATION	MODERATE
P/S	2.5	3.3
P/CFO	13.4	15.8
P/FCF	18.4	20.7
P/E	-120.1	23.5
STABILITY	FAIR
Debt/Equity	0.26	0.21
Cash/Assets	0.03	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Discovery and Safety Assessment (DSA) Backlog	1.80 billion	9272025	Link
Discovery and Safety Assessment (DSA) Net Book-to-Bill Ratio	0.82	9272025	Link
Number of Employees	20100	12312024	Link
Number of Patents (Globally)	512	11052025	Link

Upcoming
2/18/2026	Earnings Release	Rev: - EPS: -

CRL Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Charles River Laboratories International (CRL) experienced a significant stock movement of approximately 24.7% between August 31, 2025, and December 27, 2025. This upward trend can be attributed to several key factors, particularly the company's third-quarter earnings report and subsequent market reception.

1. Charles River Laboratories released its third-quarter 2025 financial results on November 5, 2025, reporting a non-GAAP earnings per share (EPS) of $2.43, which exceeded analyst expectations. This positive surprise in adjusted earnings likely contributed to investor confidence, despite other mixed results.

2. The company's revenue for the third quarter of 2025 reached $1.00 billion, aligning with analyst expectations. Meeting revenue targets is often viewed favorably by the market, providing stability amidst other financial metrics.

3. Charles River Laboratories demonstrated an improvement in its GAAP operating margin, rising to 13.3% in the third quarter of 2025 from 11.6% in the prior year, primarily driven by lower restructuring costs. This operational efficiency and cost management signal a healthier financial structure.

4. The Research Models and Services (RMS) segment showed robust growth, with revenue increasing by 7.9% in the third quarter of 2025 compared to the same period in 2024. Strong performance in a key segment can indicate underlying business strength and future growth potential.

5. The stock experienced a significant upward movement, rising approximately 25.69% from a pivot bottom point on November 19, 2025, through December 24, 2025. This strong recovery post-earnings suggests positive market sentiment and a potential re-evaluation by investors after the Q3 report and related analyst coverage.

Stock Movement Drivers

Fundamental Drivers

The 37.1% change in CRL stock from 9/26/2025 to 12/26/2025 was primarily driven by a 37.4% change in the company's P/S Multiple.

	9262025	12262025	Change
Stock Price ($)	148.56	203.66	37.09%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	4028.61	4023.70	-0.12%
P/S Multiple	1.81	2.49	37.44%
Shares Outstanding (Mil)	49.15	49.21	-0.13%
Cumulative Contribution			37.09%

LTM = Last Twelve Months as of date shown

Market Drivers

9/26/2025 to 12/26/2025

	Return	Correlation
CRL	37.1%
Market (SPY)	4.3%	34.2%
Sector (XLV)	15.2%	63.1%

Fundamental Drivers

The 35.8% change in CRL stock from 6/27/2025 to 12/26/2025 was primarily driven by a 31.8% change in the company's P/S Multiple.

	6272025	12262025	Change
Stock Price ($)	150.01	203.66	35.76%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	4022.60	4023.70	0.03%
P/S Multiple	1.89	2.49	31.81%
Shares Outstanding (Mil)	50.68	49.21	2.89%
Cumulative Contribution			35.65%

LTM = Last Twelve Months as of date shown

Market Drivers

6/27/2025 to 12/26/2025

	Return	Correlation
CRL	35.8%
Market (SPY)	12.6%	29.3%
Sector (XLV)	17.0%	60.2%

Fundamental Drivers

The 9.1% change in CRL stock from 12/26/2024 to 12/26/2025 was primarily driven by a 5.4% change in the company's P/S Multiple.

	12262024	12262025	Change
Stock Price ($)	186.65	203.66	9.11%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	4060.92	4023.70	-0.92%
P/S Multiple	2.36	2.49	5.45%
Shares Outstanding (Mil)	51.39	49.21	4.24%
Cumulative Contribution			8.92%

LTM = Last Twelve Months as of date shown

Market Drivers

12/26/2024 to 12/26/2025

	Return	Correlation
CRL	9.1%
Market (SPY)	15.8%	48.4%
Sector (XLV)	13.3%	55.5%

Fundamental Drivers

The -7.0% change in CRL stock from 12/27/2022 to 12/26/2025 was primarily driven by a -15.4% change in the company's P/S Multiple.

	12272022	12262025	Change
Stock Price ($)	218.92	203.66	-6.97%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	3781.27	4023.70	6.41%
P/S Multiple	2.95	2.49	-15.42%
Shares Outstanding (Mil)	50.87	49.21	3.26%
Cumulative Contribution			-7.07%

LTM = Last Twelve Months as of date shown

Market Drivers

12/27/2023 to 12/26/2025

	Return	Correlation
CRL	-14.7%
Market (SPY)	48.0%	48.7%
Sector (XLV)	18.2%	52.8%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
CRL Return	64%	51%	-42%	8%	-22%	10%	33%
Peers Return	16%	38%	-12%	21%	26%	16%	150%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	114%
Monthly Win Rates [3]
CRL Win Rate	83%	83%	25%	42%	33%	50%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
CRL Max Drawdown	-35%	-0%	-52%	-24%	-24%	-46%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See CRL Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique Key	Event	CRL	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-64.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	178.6%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-44.5%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	80.3%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	72 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-23.6%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	30.9%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	41 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-69.8%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	231.2%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	2,245 days	1,480 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

Charles River Laboratories International's stock fell -64.1% during the 2022 Inflation Shock from a high on 9/24/2021. A -64.1% loss requires a 178.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Charles River Laboratories International (CRL)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

AI Analysis | Feedback

1. Accenture for drug development: Like Accenture provides a wide range of consulting and professional services to businesses across industries, Charles River provides specialized contract research, testing, and development services to pharmaceutical and biotech companies, acting as an outsourced R&D partner.

2. AWS for drug discovery and testing services: Just as Amazon Web Services provides essential cloud computing infrastructure and services that companies can outsource, Charles River offers critical lab services, research models, and development support that pharmaceutical and biotech companies outsource for their drug discovery and testing processes.

AI Analysis | Feedback

Research Models: Provides genetically defined laboratory animals (e.g., mice, rats) crucial for preclinical research and drug development.
Discovery Services: Offers early-stage research support, including target validation, *in vitro* and *in vivo* pharmacology, and lead optimization.
Safety Assessment (Preclinical) Services: Conducts comprehensive toxicology, pathology, and DMPK studies to evaluate the safety of drug candidates.
Biologics Testing Solutions: Provides a suite of testing services to ensure the safety, potency, and purity of biologics, vaccines, and cell and gene therapies.
Endotoxin and Microbial Detection Solutions: Supplies products and services for detecting bacterial endotoxins and microbial contaminants in pharmaceutical and medical device manufacturing.

AI Analysis | Feedback

Charles River Laboratories International (CRL) primarily sells its products and services to other companies within the life sciences sector.

Due to the confidential nature of client relationships in the contract research organization (CRO) industry, Charles River Laboratories does not publicly disclose the specific names of its individual major customer companies. As such, it is not possible to list specific customer names with their symbols.

Instead, CRL's customer base can be broadly categorized into the following types of organizations:

Pharmaceutical Companies: This category includes a wide range of drug developers, from large, global pharmaceutical corporations to mid-sized and smaller firms. They utilize CRL's services for various stages of drug discovery, preclinical development, safety assessment, and clinical support.
Biotechnology Companies: Ranging from nascent startups to well-established biotechnology firms, these companies rely on CRL for research models, in vitro and in vivo studies, biologics testing, and other specialized services to advance their therapeutic candidates.
Academic Institutions and Government Agencies: Universities, research institutions, and government-funded laboratories also leverage CRL's expertise, resources, and research models for a wide array of biomedical research and development projects.

AI Analysis | Feedback

null

AI Analysis | Feedback

James C. Foster, Chairman, President & Chief Executive Officer
Mr. Foster is the son of Charles River Laboratories' founder, Henry Foster, and has spent his career at the company. He joined in 1976 as Vice President of Administration and General Counsel. He was named President in 1991, Chief Executive Officer in 1992, and Chairman in 2000. Under his leadership, Charles River Laboratories transformed from a niche research models and services business into a comprehensive early-stage drug research partner. He was recognized as the 2003 Forbes magazine Entrepreneur of the Year. Mr. Foster also serves as a Senior Advisor at Cell Signaling Technology and is the Chairman of the Board of Trustees of the Institute of Contemporary Art in Boston. Michael G. Knell, Interim Chief Financial Officer, Corporate Senior Vice President & Chief Accounting Officer
Mr. Knell assumed the role of Interim Chief Financial Officer in September 2025, in addition to his responsibilities as Corporate Senior Vice President and Chief Accounting Officer, a position he has held since April 2017. Before joining Charles River, he served as Chief Accounting Officer and Vice President of Finance at Bruker Corp. Earlier in his career, Mr. Knell was a Partner of Assurance Services at Ernst & Young LLP. Birgit Girshick, Corporate Executive Vice President & Chief Operating Officer
Ms. Girshick was promoted to Chief Operating Officer in October 2021. She began her career at Charles River in 1989, holding various positions of increasing responsibility within the Research Models & Services and Avian Vaccine Services businesses. Her roles included General Manager of Avian Vaccine Services, Corporate Vice President of Global Biopharmaceutical Services (now Biologics Testing Solutions), and Corporate Senior Vice President of Research Models and Biologics Testing Solutions. In her current role, Ms. Girshick is responsible for leading the Company's global business units, guiding strategic direction, driving operational excellence and growth, managing client relationships, overseeing digital transformation, and integrating acquisitions. Victoria L. Creamer, Corporate Executive Vice President & Chief People Officer
Ms. Creamer serves as the Corporate Executive Vice President and Chief People Officer at Charles River Laboratories. She joined Charles River in May 2011 as Corporate Vice President, Human Resources. She was promoted to Corporate Senior Vice President in 2013 and to Corporate Executive Vice President in 2016. Prior to joining Charles River, she held various human resources leadership positions at Boston Scientific Corporation, including Vice President of Human Resources. She also worked in human resources at Pepsi-Cola Company. Mark Mintz, Corporate Executive Vice President, Chief Information Officer & Global Shared Services
Mr. Mintz is the Corporate Executive Vice President, Chief Information Officer & Global Shared Services. He was appointed Corporate Senior Vice President and Chief Information Officer in 2021, having previously served as Corporate Senior Vice President and Chief Digital Officer. Before joining Charles River, Mr. Mintz was a founding member of McKinsey & Company's digital labs. His experience also includes roles as an Application Development Manager at DoubleClick and a Technology Consultant at Accenture, bringing over 25 years of IT and digital expertise to his position.

AI Analysis | Feedback

The public company Charles River Laboratories International (CRL) faces several significant business risks, primarily stemming from macroeconomic conditions, evolving regulatory landscapes, and operational complexities.

Declining Biopharmaceutical R&D Spending and Macroeconomic Headwinds

Charles River Laboratories is experiencing significant revenue challenges due to macroeconomic uncertainties, particularly in regions like China, and reduced spending from its global biopharmaceutical clients. This downturn in pharmaceutical R&D spending and tightening biopharma budgets are directly pressuring CRL's business, with organic revenue expected to decline. The company's CEO attributed lower revenue projections for 2025 to low client spending on drug discovery and safety services, along with other factors.
FDA's Phase-out of Animal Testing

A major regulatory risk for Charles River Laboratories is the FDA's decision to phase out animal testing requirements. This move directly impacts the company's core business, which heavily relies on research model services (RMS). While RMS constitutes approximately 20% of CRL's revenue, its higher operating margin means the potential impact on net income could be substantial, representing a significant long-term challenge to a foundational segment of the company.
Production, Quality Control, and Supply Chain Risks

Charles River Laboratories faces risks related to its complex manufacturing services. Failures in quality control systems within its facilities could lead to product destruction, delays in delivery, damage to the company's reputation and customer relationships, and revenue loss. Additionally, the company's financial performance can suffer if its Contract Development and Manufacturing Organization (CDMO) customers fail to secure or maintain regulatory approval for their products, or if CRL's own manufacturing facilities do not receive FDA approval. Supply chain issues, such as constraints on non-human primate (NHP) availability and associated regulatory investigations, also pose a risk to the business.

AI Analysis | Feedback

Accelerated adoption of New Approach Methodologies (NAMs) in drug development, driven by regulatory changes: The passage of the FDA Modernization Act 2.0 in December 2022 removed the federal mandate for animal testing in new drug approvals, enabling the use of alternative methods. This legislative shift provides a significant tailwind for the widespread adoption of technologies such as organ-on-a-chip, microphysiological systems, and advanced *in silico* modeling, which could substantially reduce or replace the demand for traditional *in vivo* (animal) preclinical testing. As a core provider of *in vivo* research models and safety assessment services, a rapid industry-wide pivot towards NAMs could threaten a significant portion of CRL's established revenue streams, even as CRL also invests in these new technologies.
Persistent supply chain constraints and rising costs for non-human primates (NHPs): Ongoing export restrictions from key NHP supplier countries (e.g., Cambodia) and increasing global demand have created significant shortages and escalated prices for these essential research models. This directly impacts CRL's ability to procure and supply NHPs for its Research Models and Services segment and to conduct NHP-dependent studies within its Discovery and Safety Assessment segment, leading to increased operational costs and potential limitations on service delivery.

AI Analysis | Feedback

Charles River Laboratories International (CRL) provides a comprehensive range of products and services primarily for drug discovery, development, and manufacturing support. The addressable markets for their main offerings globally are:

Contract Research Organization (CRO) Services: The global contract research organization (CRO) services market was valued at approximately USD 79.10 billion in 2024 and is projected to advance to USD 125.95 billion by 2030.
Preclinical CRO Services: The global preclinical CRO market was estimated at USD 6.19 billion in 2024 and is projected to reach USD 12.37 billion by 2033.
Drug Discovery Services: The global drug discovery services market was valued at USD 14.89 billion in 2024 and is projected to reach USD 27.23 billion by 2030. Another estimate puts the global drug discovery services market at USD 21.26 billion in 2024, expected to exceed USD 79.71 billion by 2034.
Pharmaceutical Safety Assessment (including In Vivo Toxicology): The global pharmaceutical safety assessment market is projected to reach approximately USD 15 billion by 2025, with a compound annual growth rate (CAGR) of 8.5% anticipated through 2033. Specifically, the global in vivo toxicology market was valued at USD 4.95 billion in 2024 and is expected to reach USD 7.66 billion by 2032.
Biologics Testing Services: The global biologics safety testing market size was approximately USD 4.03 billion in 2024 and is projected to reach USD 14.45 billion by 2034.
Cell and Gene Therapy CDMO Services: The global cell and gene therapy CDMO market size was valued at USD 4.31 billion in 2024 and is projected to reach USD 27.12 billion by 2033.
Microbial Solutions: The global microbial products market size was accounted for USD 209.67 billion in 2024 and is anticipated to reach around USD 351.42 billion by 2034.

AI Analysis | Feedback

Charles River Laboratories International (CRL) is expected to drive future revenue growth over the next 2-3 years through several key strategies and market trends:

Recovery in Biotech Funding and Demand: Management anticipates a recovery in the biotech funding environment, which is expected to translate into increased demand and higher study volumes, particularly for the Discovery and Safety Assessment (DSA) segment. Positive signals are emerging in biotech funding, which could lead to a recovery in demand over the next year, boosting bookings from small and mid-sized biotech clients.
Continued Growth in Research Models and Services (RMS) Segment: The Research Models and Services (RMS) segment has demonstrated consistent revenue growth, with a notable 7.9% increase in Q3 2025, driven primarily by strong performance in large research model products. This segment is expected to continue to be a reliable contributor to overall revenue expansion.
Strategic Portfolio Refinement: Charles River Laboratories is undertaking a strategic review that includes planned divestitures of underperforming assets. This initiative aims to streamline the company's portfolio, allowing it to concentrate on core, high-growth segments and improve overall earnings accretion.
Operational Efficiency and Cost Savings Initiatives: The company is implementing comprehensive restructuring initiatives and operational efficiency measures designed to generate significant cost savings. These measures, including workforce optimization, procurement savings, and automation, are projected to yield approximately $225 million in cumulative, annualized cost savings by 2026, with additional incremental net cost savings of about $70 million annually. While primarily impacting profitability, these efficiencies can support revenue growth by enabling more competitive pricing and allowing for reinvestment into growth opportunities.

AI Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years) for Charles River Laboratories International (CRL)

Share Repurchases

A new $1.0 billion stock repurchase authorization was approved in October 2025, replacing a previous authorization under which $450.7 million in common stock had been repurchased since August 2024.
The company repurchased approximately $100 million in shares during the third quarter of 2024.
In the first quarter of 2025, Charles River Laboratories repurchased $350 million in shares.

Share Issuance

Charles River Laboratories International's Issuance of Stock for the trailing twelve months (TTM) ended June 2025 was €0.00 million.

Outbound Investments

In February 2021, Charles River acquired Cognate BioServices, Inc. for $875 million.
The company acquired Vigene Biosciences in May 2021 for $292 million.
In November 2023, an additional 41% stake in Noveprim Limited was acquired for approximately $210 million, strengthening the supply chain for the DSA segment.

Capital Expenditures

Capital expenditures averaged $254.3 million from fiscal years ending December 2020 to 2024, peaking at $324.7 million in December 2022.
The latest twelve months ending June 28, 2025, saw capital expenditures of $209 million.
A focus of capital expenditures includes strategic investments in automation and digitalization, expected to contribute to over $175 million in annualized savings for 2025.

Better Bets than Charles River Laboratories International (CRL)

INDUSTRY: Life Sciences Tools & Services

Higher Rev Chg 3Y Avg | Lower P/S (Values for CRL: 2.3% | 2.5x)

IQV (3.6% | 2.4x)

IQVIA

NVCR (6.2% | 2.3x)

NovoCure

TCMD (10.0% | 2.1x)

Tactile Systems Technology

OFIX (21.9% | 0.7x)

Orthofix Medical

BVS (3.1% | 0.9x)

Bioventus

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for CRL: 2.3% | 28.2x)

IQV (3.6% | 17.1x)

IQVIA

BVS (3.1% | 10.3x)

Bioventus

VMD (24.2% | 16.2x)

Viemed Healthcare

ELMD (16.1% | 22.8x)

Electromed

XTNT (33.5% | 17.2x)

Xtant Medical

Higher Rev Chg LTM (Value for CRL: -0.9%)

NTRA (38.2%)

Natera

A (6.7%)

Agilent Technologies

IQV (3.8%)

IQVIA

TMO (3.2%)

Thermo Fisher Scientific

DHR (2.2%)

Danaher

Higher Rev Chg 3Y Avg (Value for CRL: 2.3%)

NTRA (40.2%)

Natera

GH (28.0%)

Guardant Health

MEDP (19.9%)

Medpace

EXAS (15.5%)

Exact Sciences

IQV (3.6%)

IQVIA

Higher Op Mgn LTM (Value for CRL: 8.8%)

MTD (28.1%)

Mettler-Toledo International

A (21.3%)

Agilent Technologies

DHR (19.0%)

Danaher

TMO (18.4%)

Thermo Fisher Scientific

IQV (14.2%)

IQVIA

Higher CFO/Rev LTM (Value for CRL: 18.6%)

ILMN (26.2%)

Illumina

DHR (26.0%)

Danaher

MTD (25.3%)

Mettler-Toledo International

WAT (23.4%)

Waters

A (22.4%)

Agilent Technologies

Higher FCF/Rev LTM (Value for CRL: 13.5%)

MTD (22.6%)

Mettler-Toledo International

DHR (20.7%)

Danaher

A (16.6%)

Agilent Technologies

TMO (14.0%)

Thermo Fisher Scientific

IQV (13.9%)

IQVIA

Higher Total Yield (Value for CRL: -0.8%)

A (4.1%)

Agilent Technologies

IQV (3.3%)

IQVIA

TMO (3.0%)

Thermo Fisher Scientific

MTD (2.9%)

Mettler-Toledo International

DHR (2.1%)

LLY (1.9%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for CRL: 2.3% | 2.5x)

WMT (5.4% | 1.3x)

Walmart

COST (6.7% | 1.4x)

Costco Wholesale

DIS (4.5% | 2.2x)

Walt Disney

PEP (3.4% | 2.1x)

PepsiCo

ACN (4.3% | 2.4x)

Accenture

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for CRL: 2.3% | 28.2x)

MSFT (13.2% | 26.7x)

Microsoft

META (17.3% | 20.4x)

Meta Platforms

V (10.9% | 17.3x)

Visa

MU (28.3% | 23.3x)

Micron Technology

CSCO (3.7% | 23.8x)

Cisco Systems

Higher Rev Chg LTM (Value for CRL: -0.9%)

NVDA (65.2%)

NVIDIA

MSFT (15.6%)

Microsoft

GOOGL (13.4%)

Alphabet

AMZN (10.9%)

Amazon.com

AAPL (6.0%)

Apple

Higher Rev Chg 3Y Avg (Value for CRL: 2.3%)

NVDA (91.6%)

NVIDIA

META (17.3%)

Meta Platforms

MSFT (13.2%)

Microsoft

AMZN (11.3%)

Amazon.com

GOOGL (11.0%)

Alphabet

Higher Op Mgn LTM (Value for CRL: 8.8%)

NVDA (58.8%)

NVIDIA

MSFT (46.3%)

Microsoft

GOOGL (32.2%)

Alphabet

AAPL (31.9%)

Apple

AMZN (11.4%)

Amazon.com

Higher CFO/Rev LTM (Value for CRL: 18.6%)

META (56.8%)

Meta Platforms

MSFT (50.0%)

Microsoft

NVDA (44.4%)

NVIDIA

GOOGL (39.3%)

Alphabet

AAPL (26.6%)

Apple

Higher FCF/Rev LTM (Value for CRL: 13.5%)

NVDA (41.3%)

NVIDIA

MSFT (26.6%)

Microsoft

META (23.7%)

Meta Platforms

AAPL (23.5%)

Apple

GOOGL (19.1%)

Alphabet

Higher Total Yield (Value for CRL: -0.8%)

MSFT (3.6%)

Microsoft

GOOGL (3.5%)

Alphabet

AMZN (2.9%)

Amazon.com

AAPL (2.8%)

Apple

NVDA (2.2%)

NVIDIA

		Best Bets In Health Care Sector
	CRL	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	-120.1	22.1	13.6	32.4	13.7	11.8	78.9	75.0	28.1	11.4	58.0
P/EBIT	112.2	10.7	10.6	33.2	11.5	8.9	57.4	73.2	27.4	7.7	67.5
What You Get
Rev Chg Q	-0.5%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	-0.9%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	2.3%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	12.0%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Charles River Laboratories International Earnings Notes
2	Charles River Laboratories International Earnings Notes
3	5-Day Rally Sends Charles River Laboratories International Stock Up 11%	Notification
4	Charles River Laboratories International Stock: High Cash Flow - Why Not Watch It?	Actionable
5	Day 5 of Gains Streak for Charles River Laboratories International Stock with 11% Return (vs. 2% YTD) [10/21/2025]	Notification
6	Day 5 of Gains Streak for Charles River Laboratories International Stock with 11% Return (vs. 2% YTD) [10/21/2025]	Notification
7	Day 5 of Gains Streak for Charles River Laboratories International Stock with 11% Return (vs. 2% YTD) [10/21/2025]	Notification
8	Is Charles River Laboratories International Stock Built to Withstand a Pullback?	Return
9	Day 8 of Gains Streak for Charles River Laboratories International Stock with 7.3% Return (vs. -14% YTD) [8/20/2025]	Notification
10	Day 7 of Gains Streak for Charles River Laboratories International Stock with 6.5% Return (vs. -14% YTD) [8/19/2025]	Notification

	Title
0	ARTICLES

Trade Ideas

Select ideas related to CRL. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.1%	21.1%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-6.7%	-6.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	16.7%	16.7%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	11.8%	11.8%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ZETA	Zeta Global	4.6	8.3%	15.1%
SGML	Sigma Lithium	1.6	7.3%	29.2%
USAS	Americas Gold And Silver	1.6	6.6%	557.6%
CPNG	Coupang	44.2	6.4%	10.4%
LION	Lionsgate Studios	2.7	4.6%	-69.9%
BBW	Build-A-Bear Workshop	0.8	4.4%	37.8%
XRAY	Dentsply Sirona	2.3	4.2%	-36.3%
BLMN	Bloomin Brands	0.6	3.8%	-41.2%
FUN	Six Flags Entertainment	1.5	3.8%	-69.1%
SVM	Silvercorp Metals	1.9	3.6%	198.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	3.3	-13.7%	-61.3%
TMC	TMC The Metals	2.5	-10.5%	508.9%
ORGO	Organogenesis	0.7	-10.1%	64.8%
AAOI	Applied Optoelectronics	2.4	-9.3%	0.8%
BKSY	BlackSky Technology	0.7	-9.0%	79.0%
LUNR	Intuitive Machines	1.8	-8.7%	-16.0%
RCAT	Red Cat	0.8	-8.7%	-35.4%
RGTI	Rigetti Computing	6.7	-8.7%	46.7%
RDW	Redwire	1.0	-8.6%	-56.6%
RKLB	Rocket Lab	36.4	-8.5%	177.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	71.5%	59.0%
RZLT	Rezolute	0.3	44.3%	-45.5%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
LUNR	Intuitive Machines	1.8	40.6%	-16.0%
UAMY	United States Antimony	0.7	39.0%	252.5%
FOLD	Amicus Therapeutics	4.4	30.9%	51.3%
ADEA	Adeia	1.9	30.3%	23.0%
HUT	Hut 8	5.2	28.6%	142.3%
AAOI	Applied Optoelectronics	2.4	27.1%	0.8%
SGML	Sigma Lithium	1.6	24.9%	29.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.6	-67.9%	-21.5%
LW	Lamb Weston	5.9	-29.0%	-35.3%
TLRY	Tilray Brands	10.2	-22.2%	-27.8%
TDUP	ThredUp	0.8	-18.2%	348.2%
LAB	Standard BioTools	0.5	-16.9%	-21.1%
OLMA	Olema Pharmaceuticals	2.2	-14.9%	349.9%
EVEX	Eve	1.4	-12.0%	-21.9%
IRON	Disc Medicine	2.8	-11.2%	26.7%
AVO	Mission Produce	0.8	-11.1%	-18.8%
CABO	Cable One	0.7	-10.6%	-67.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	10.2	876.4%	-27.8%
HPP	Hudson Pacific Properties	4.7	452.7%	-51.0%
WVE	WAVE Life Sciences	2.9	139.2%	43.7%
TE	T1 Energy	1.1	106.7%	400.0%
VERA	Vera Therapeutics	3.4	82.1%	26.7%
OMER	Omeros	0.9	66.2%	59.0%
RKLB	Rocket Lab	36.4	65.8%	177.4%
PL	Planet Labs PBC	5.9	65.0%	379.2%
AAOI	Applied Optoelectronics	2.4	63.5%	0.8%
LUNR	Intuitive Machines	1.8	62.4%	-16.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-45.5%
JANX	Janux Therapeutics	0.9	-59.0%	-73.4%
FRMI	Fermi	5.3	-46.0%	-76.6%
LENZ	LENZ Therapeutics	0.5	-43.5%	-41.6%
GOGO	Gogo	0.6	-35.3%	-43.0%
HPK	HighPeak Energy	0.5	-33.9%	-70.4%
PACB	Pacific Biosciences of California	0.5	-32.7%	-3.3%
LDI	loanDepot	0.4	-29.6%	3.9%
ORIC	ORIC Pharmaceuticals	0.6	-29.0%	2.2%
LW	Lamb Weston	5.9	-28.6%	-35.3%

Peer Comparisons for Charles River Laboratories International

Peers to compare with:

Financials

	CRL	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Charles .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	203.66	23.26	24.49	305.09	78.16	273.40	140.91
Mkt Cap	10.0	21.9	32.6	284.9	309.2	4,074.4	158.8
Rev LTM	4,024	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	356	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	544	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	491	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	749	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	748	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	CRL	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Charles .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	-0.9%	3.2%	13.8%	4.5%	8.9%	6.0%	5.2%
Rev Chg 3Y Avg	2.3%	-3.9%	6.5%	2.6%	3.7%	1.8%	2.5%
Rev Chg Q	-0.5%	4.2%	14.4%	9.1%	7.5%	9.6%	8.3%
QoQ Delta Rev Chg LTM	-0.1%	1.1%	3.7%	2.1%	1.8%	2.1%	2.0%
Op Mgn LTM	8.8%	6.6%	4.8%	17.7%	22.5%	31.9%	13.2%
Op Mgn 3Y Avg	12.4%	7.4%	7.2%	16.4%	24.2%	30.8%	14.4%
QoQ Delta Op Mgn LTM	0.4%	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.2%
CFO/Rev LTM	18.6%	6.7%	8.5%	20.6%	23.8%	26.6%	19.6%
CFO/Rev 3Y Avg	18.3%	6.8%	12.7%	21.4%	26.1%	28.4%	19.8%
FCF/Rev LTM	13.5%	5.1%	1.8%	18.1%	22.1%	23.5%	15.8%
FCF/Rev 3Y Avg	12.0%	5.5%	4.6%	18.6%	24.6%	25.6%	15.3%

Valuation

	CRL	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Charles .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	10.0	21.9	32.6	284.9	309.2	4,074.4	158.8
P/S	2.5	0.4	1.0	4.4	5.4	10.0	3.4
P/EBIT	112.2	6.8	19.9	25.1	22.5	31.3	23.8
P/E	-120.1	8.6	572.7	36.0	29.9	41.0	33.0
P/CFO	13.4	5.9	11.2	21.1	22.5	37.5	17.3
Total Yield	-0.8%	14.1%	2.3%	5.0%	5.4%	2.8%	3.9%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	5.4%	10.6%	5.5%	6.4%	6.0%	3.1%	5.7%
D/E	0.3	0.5	0.7	0.2	0.1	0.0	0.2
Net D/E	0.2	0.3	0.6	0.2	0.0	0.0	0.2

Returns

	CRL	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Charles .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	13.8%	-1.8%	14.4%	0.6%	2.7%	-1.5%	1.7%
3M Rtn	37.1%	-11.9%	2.7%	7.9%	17.0%	7.1%	7.5%
6M Rtn	35.8%	-4.0%	34.5%	6.6%	15.2%	36.3%	24.9%
12M Rtn	9.1%	-27.3%	14.2%	39.2%	33.7%	6.0%	11.6%
3Y Rtn	-7.0%	-3.8%	67.7%	139.0%	79.5%	113.4%	73.6%
1M Excs Rtn	12.0%	-5.6%	12.9%	-2.2%	-0.0%	-3.7%	-1.1%
3M Excs Rtn	32.8%	-16.2%	-1.7%	3.6%	12.7%	2.8%	3.2%
6M Excs Rtn	23.5%	-16.3%	22.3%	-5.7%	3.0%	24.0%	12.6%
12M Excs Rtn	-6.1%	-42.9%	-0.7%	25.0%	19.9%	-8.4%	-3.4%
3Y Excs Rtn	-85.7%	-83.5%	-11.2%	59.6%	-1.2%	28.4%	-6.2%

FDIC Bank Data

$ Mil \| FY: 12/30	LTM	2024	2023	2022	2021	2020	2019
Period End	9/27/2025	12/30/2024	12/30/2023	12/31/2022	12/31/2021	12/26/2020	12/28/2019
Filing Date	11/5/2025	2/19/2025	2/14/2024	2/22/2023	2/16/2022	2/17/2021	2/11/2020
Key Financials
Total Revenue	4,024	4,050	4,129	3,976	3,540	2,924	2,621
EBITDA	516	581	1,032	986	820	768	563
Operating Income	356	442	617	651	590	433	351
Net Income	-83	10	475	486	391	364	252
EPS	-1.55	0.20	9.27	9.57	7.77	7.35	5.17
Growth Rates
Total Revenue Growth	-0.9%	-1.9%	3.9%	12.3%	21.1%	11.5%	15.7%
EBITDA Growth	-47.9%	-43.7%	4.7%	20.2%	6.7%	36.5%	11.0%
Operating Income Growth	-32.6%	-28.3%	-5.2%	10.4%	36.3%	23.2%	6.0%
Net Income Growth	-120.2%	-97.8%	-2.4%	24.4%	7.3%	44.6%	11.3%
Margins
EBITDA Margin	12.8%	14.3%	25.0%	24.8%	23.2%	26.3%	21.5%
Operating Income Margin	8.8%	10.9%	14.9%	16.4%	16.7%	14.8%	13.4%
Net Income Margin	-2.1%	0.3%	11.5%	12.2%	11.0%	12.5%	9.6%
Cash & Debt
Total Cash	207	195	277	234	242	229	239
Total Debt	2,629	2,724	3,066	3,097	2,917	2,160	2,025
Net Debt / (Cash)	2,422	2,529	2,790	2,863	2,674	1,931	1,786
Cash Flows
Net Cash from Operations	749	735	684	620	761	547	481
Free Cash from Operations	544	502	365	295	532	380	340
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	361	119	24	39	41	24	18

$ Mil \| FY: 12/30	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/27/2025	6/28/2025	3/29/2025	12/30/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022
Filing Date	11/5/2025	8/6/2025	5/7/2025	2/19/2025	11/6/2024	8/7/2024	5/9/2024	2/14/2024	11/8/2023	8/9/2023	5/11/2023	2/22/2023
Key Financials Quarterly
Total Revenue	1,005	1,032	984	1,003	1,010	1,026	1,012	1,013	1,027	1,060	1,029	1,100
Ebitda	198	221	184	-86	210	239	219	323	225	241	242	357
Operating Income	134	100	75	47	117	152	126	133	152	165	168	164
Net Income	54	52	25	-216	69	90	67	187	87	97	103	187
EPS	1.11	1.06	0.50	-4.22	1.34	1.75	1.31	3.65	1.70	1.89	2.02	3.68
Key Financials TTM
Total Revenue TTM	4,024	4,029	4,023	4,050	4,061	4,078	4,112	4,129	4,216	4,178	4,092	3,976
Ebitda TTM	516	528	546	581	990	1,006	1,009	1,032	1,067	1,050	1,033	986
Operating Income TTM	356	340	391	442	528	562	575	617	648	648	670	651
Net Income TTM	-83	-69	-32	10	413	432	439	475	475	484	496	486
Growth Rates Quarterly
Total Revenue Growth	-0.5%	0.6%	-2.7%	-1.1%	-1.6%	-3.2%	-1.7%	-7.9%	3.8%	8.9%	12.6%	21.5%
EBITDA Growth	-5.7%	-7.4%	-16.0%	-126.8%	-7.0%	-1.2%	-9.5%	-9.7%	7.8%	7.6%	24.0%	47.4%
Operating Income Growth	14.0%	-34.0%	-40.7%	-64.4%	-22.5%	-8.1%	-25.0%	-18.9%	0.3%	-12.0%	12.8%	-5.2%
Net Income Growth	-20.8%	-41.9%	-62.2%	-215.3%	-21.4%	-7.2%	-34.7%	-0.2%	-9.4%	-11.3%	10.9%	36.2%
Margins Quarterly
EBITDA Margin	19.7%	21.4%	18.7%	-8.6%	20.8%	23.2%	21.7%	31.8%	22.0%	22.8%	23.6%	32.5%
Operating Income Margin	13.3%	9.7%	7.6%	4.7%	11.6%	14.8%	12.5%	13.1%	14.8%	15.6%	16.3%	14.9%
Net Income Margin	5.4%	5.1%	2.6%	-21.5%	6.8%	8.8%	6.7%	18.5%	8.5%	9.2%	10.0%	17.0%
Cash & Debt
Total Cash	207	183	229	195	210	179	327	277	157	200	202	234
Total Debt	2,629	2,786	2,986	2,724	2,759	2,838	3,079	3,066	2,905	3,080	3,162	3,097
Net Debt / (Cash)	2,422	2,603	2,757	2,529	2,549	2,659	2,751	2,790	2,747	2,880	2,960	2,863
Cash Flows Quarterly
FCF from Operations	214	205	172	159	252	194	130	221	205	148	109	235
Cash Flows TTM
FCF from Operations TTM	749	787	776	735	796	750	704	684	698	625	626	620
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	7	353	0	101	9	9	0	0	5	19	0
Return on Invested Capital (ROIC) Quarterly
ROIC	9.7%	8.0%	5.7%	4.5%	8.8%	11.1%	8.6%	10.7%	11.0%	11.4%	11.8%	11.5%
Return on Invested Capital (ROIC) TTM
ROIC TTM	10.1%	9.2%	10.4%	2.9%	10.7%	10.8%	10.7%	11.3%	11.7%	11.3%	11.6%	11.7%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Discovery and Safety Assessment (DSA)	2,616	2,447	2,107	1,837	1,619
Research Models and Services (RMS)	792	739	690	571	537
Manufacturing	721	790	742	515	465
Total	4,129	3,976	3,540	2,924	2,621

Operating Income by Segment

$ Mil	2024	2023	2022	2021	2020
Discovery and Safety Assessment (DSA)	606	533	407	326	259
Research Models and Services (RMS)	155	160	167	103	134
Manufacturing	88	167	246	181	145
Unallocated Corporate	-232	-209	-230	-177	-187
Total	617	651	590	433	351

Price Behavior

Price Behavior

Market Price	$203.66
Market Cap ($ Bil)	10.0
First Trading Date	06/23/2000
Distance from 52W High	0.0%
	50 Days	200 Days
DMA Price	$182.24	$157.99
DMA Trend	up	up
Distance from DMA	11.8%	28.9%
	3M	1YR
Volatility	40.0%	54.2%
Downside Capture	32.43	144.26
Upside Capture	177.87	132.24
Correlation (SPY)	35.0%	48.4%

CRL Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.77	1.04	1.17	1.15	1.32	1.34
Up Beta	2.34	2.00	2.36	1.03	1.09	1.23
Down Beta	-0.26	0.88	0.53	1.03	1.57	1.28
Up Capture	50%	133%	122%	147%	140%	197%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	9	21	28	66	123	364
Down Capture	53%	49%	101%	105%	126%	109%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	10	20	34	58	124	385

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of CRL With Other Asset Classes (Last 1Y)
	CRL	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	9.6%	15.1%	17.8%	72.1%	8.6%	4.4%	-8.3%
Annualized Volatility	53.9%	17.2%	19.4%	19.3%	15.2%	17.0%	35.0%
Sharpe Ratio	0.37	0.65	0.72	2.70	0.34	0.09	-0.08
Correlation With Other Assets		55.4%	48.3%	-8.1%	12.0%	44.6%	19.2%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of CRL With Other Asset Classes (Last 5Y)
	CRL	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-3.8%	8.4%	14.7%	18.7%	11.5%	4.6%	30.8%
Annualized Volatility	40.9%	14.5%	17.1%	15.5%	18.7%	18.9%	48.7%
Sharpe Ratio	0.03	0.40	0.70	0.97	0.50	0.16	0.57
Correlation With Other Assets		52.7%	52.6%	1.7%	8.3%	46.5%	21.8%

Based On 10-Year Data

		Comparison of CRL With Other Asset Classes (Last 10Y)
	CRL	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	9.9%	9.9%	14.8%	15.3%	7.0%	5.3%	69.2%
Annualized Volatility	36.6%	16.6%	18.0%	14.7%	17.6%	20.8%	55.8%
Sharpe Ratio	0.37	0.49	0.71	0.86	0.32	0.22	0.90
Correlation With Other Assets		59.1%	59.0%	1.6%	16.9%	49.0%	18.1%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	2,409,632
Short Interest: % Change Since 11302025	-6.4%
Average Daily Volume	817,021
Days-to-Cover Short Interest	2.95
Basic Shares Quantity	49,213,000
Short % of Basic Shares	4.9%

Returns Analyses

	Title
0	Is Charles River Laboratories International Stock Built to Withstand a Pullback?
1	CRL YTD Stock Return Of -12% Underperforms WAT by -0.2% and Underperforms MTD by -29%
2	Charles River Laboratories International Stock Return Comparison
3	Charles River Laboratories International Total Shareholder Return (TSR): -42.2% in 2022 and 12.6% 3-yr returns (below peer average)
4	Charles River Laboratories International (CRL) Stock Return: AI Predicts CRL Average and Excess Return After a Fall or Rise
5	Life Sciences Tools & Services Industry Return: 39% YTD Return vs 17% For S&P 500

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/5/2025	-5.7%	-2.4%	3.6%
8/6/2025	-10.2%	-8.8%	-3.1%
5/7/2025	18.7%	24.8%	22.3%
2/19/2025	6.9%	8.2%	12.6%
11/6/2024	13.5%	14.4%	1.5%
8/7/2024	-12.6%	-11.1%	-16.4%
5/9/2024	-2.2%	-1.2%	-8.7%
2/14/2024	11.3%	9.5%	18.3%
...
SUMMARY STATS
# Positive	15	12	13
# Negative	9	12	11
Median Positive	5.1%	8.9%	7.9%
Median Negative	-9.1%	-8.8%	-9.9%
Max Positive	18.7%	24.8%	24.2%
Max Negative	-12.6%	-12.0%	-19.4%

	Forward Returns
11/5/2025	-5.7%	-2.4%	3.6%
8/6/2025	-10.2%	-8.8%	-3.1%
5/7/2025	18.7%	24.8%	22.3%
2/19/2025	6.9%	8.2%	12.6%
11/6/2024	13.5%	14.4%	1.5%
8/7/2024	-12.6%	-11.1%	-16.4%
5/9/2024	-2.2%	-1.2%	-8.7%
2/14/2024	11.3%	9.5%	18.3%
11/8/2023	-3.7%	-2.4%	10.9%
8/9/2023	4.6%	1.9%	-0.9%
5/11/2023	5.1%	5.6%	6.1%
2/22/2023	-10.1%	-10.0%	-19.4%
11/2/2022	4.1%	7.3%	9.1%
8/3/2022	-9.1%	-12.0%	-15.8%
5/4/2022	2.5%	-8.7%	-2.4%
2/16/2022	-2.4%	-9.3%	-9.9%
11/3/2021	-10.2%	-11.2%	-15.3%
8/4/2021	1.2%	-1.0%	7.9%
5/4/2021	2.1%	0.3%	-0.7%
2/17/2021	4.4%	-1.3%	2.1%
10/29/2020	3.1%	12.3%	3.7%
8/5/2020	6.9%	3.1%	7.9%
5/7/2020	9.0%	12.0%	24.2%
2/11/2020	9.9%	11.5%	-13.4%
SUMMARY STATS
# Positive	15	12	13
# Negative	9	12	11
Median Positive	5.1%	8.9%	7.9%
Median Negative	-9.1%	-8.8%	-9.9%
Max Positive	18.7%	24.8%	24.2%
Max Negative	-12.6%	-12.0%	-19.4%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11052025	10-Q 9/27/2025
6302025	8062025	10-Q 6/28/2025
3312025	5072025	10-Q 3/29/2025
12312024	2192025	10-K 12/30/2024
9302024	11062024	10-Q 9/28/2024
6302024	8072024	10-Q 6/29/2024
3312024	5092024	10-Q 3/30/2024
12312023	2142024	10-K 12/30/2023
9302023	11082023	10-Q 9/30/2023
6302023	8092023	10-Q 7/1/2023
3312023	5112023	10-Q 4/1/2023
12312022	2222023	10-K 12/31/2022
9302022	11022022	10-Q 9/24/2022
6302022	8032022	10-Q 6/25/2022
3312022	5042022	10-Q 3/26/2022
12312021	2162022	10-K 12/31/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	LaPlume Joseph W	EVP, Corp Strategy & Develop	8202025	Sell	157.60	800	126,080	3,800,682	Form
1	LaPlume Joseph W	EVP, Corp Strategy & Develop	8082025	Sell	150.04	400	60,016	3,738,397	Form
2	MASSARO GEORGE		5162025	Sell	136.32	35	4,771	774,298	Form
3	MASSARO GEORGE		5152025	Sell	139.95	91	12,735	806,672	Form
4	LaPlume Joseph W	EVP, Corp Strategy & Develop	5152025	Sell	145.41	500	72,705	2,837,385	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Charles River Laboratories International (CRL)

Market Price (12/27/2025): $203.7 | Market Cap: $10.0 BilSector: Health Care | Industry: Life Sciences Tools & Services

Charles River Laboratories International (CRL)

Market Price (12/27/2025): $203.7Market Cap: $10.0 BilSector: Health CareIndustry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

CRL Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Charles River Laboratories International (CRL)

Declining Biopharmaceutical R&D Spending and Macroeconomic Headwinds

FDA's Phase-out of Animal Testing

Production, Quality Control, and Supply Chain Risks

Capital Allocation Decisions (Last 3-5 Years) for Charles River Laboratories International (CRL)

Share Repurchases

Share Issuance

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than Charles River Laboratories International (CRL)

INDUSTRY: Life Sciences Tools & Services

Higher Rev Chg 3Y Avg | Lower P/S (Values for CRL: 2.3% | 2.5x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for CRL: 2.3% | 28.2x)

Higher Rev Chg LTM (Value for CRL: -0.9%)

Higher Rev Chg 3Y Avg (Value for CRL: 2.3%)

Higher Op Mgn LTM (Value for CRL: 8.8%)

Higher CFO/Rev LTM (Value for CRL: 18.6%)

Higher FCF/Rev LTM (Value for CRL: 13.5%)

Higher Total Yield (Value for CRL: -0.8%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for CRL: 2.3% | 2.5x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for CRL: 2.3% | 28.2x)

Higher Rev Chg LTM (Value for CRL: -0.9%)

Higher Rev Chg 3Y Avg (Value for CRL: 2.3%)

Higher Op Mgn LTM (Value for CRL: 8.8%)

Higher CFO/Rev LTM (Value for CRL: 18.6%)

Higher FCF/Rev LTM (Value for CRL: 13.5%)

Higher Total Yield (Value for CRL: -0.8%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for CRL: 2.3% | 2.5x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for CRL: 2.3% | 28.2x)

Higher Rev Chg LTM (Value for CRL: -0.9%)

Higher Rev Chg 3Y Avg (Value for CRL: 2.3%)

Higher Op Mgn LTM (Value for CRL: 8.8%)

Higher CFO/Rev LTM (Value for CRL: 18.6%)

Higher FCF/Rev LTM (Value for CRL: 13.5%)

Higher Total Yield (Value for CRL: -0.8%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Charles River Laboratories International

Financials

Growth & Margins

Valuation

Returns

Market Price (12/27/2025): $203.7 | Market Cap: $10.0 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (12/27/2025): $203.7
Market Cap: $10.0 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services